Therapy News and Research

RSS

p62 and ERK proteins lead to development of obesity and insulin resistance, say scientists

New research by University of Cincinnati scientists implicates a new protein in obesity development and highlights a protein pair's "team effort" in regulating obesity and insulin resistance.

15 Feb 2010

Spanish-language media campaign increases number of QuitLine callers

It pays to advertise. It especially pays to advertise in Spanish if you want Spanish speakers to use a telephone helpline to quit smoking.

12 Feb 2010

Merck returns worldwide development and commercialization rights for AN2690 to Anacor Pharmaceuticals

Anacor Pharmaceuticals announced today that Merck has returned full worldwide development and commercialization rights for AN2690 to Anacor. AN2690 is a topical anti-fungal therapy being developed for onychomycosis, a fungal infection of the nail and nail bed. It is estimated that onychomycosis affects approximately 35 million people in the United States.

12 Feb 2010

New research finds sensory cortex develops late in fragile X syndrome defect

Why do people with fragile X syndrome, a genetic defect that is the best-known cause of autism and inherited mental retardation, recoil from hugs and physical touch - even from their parents?

12 Feb 2010

Adult stem cell transplant therapy may help prevent amputations from PAD

Grant Medical Center recently completed the nation's first published study of a new procedure that may give hope to millions of patients facing lower limb amputations from peripheral arterial disease (PAD). PAD is a painful circulatory problem in the legs that affects 10 million Americans. If left untreated, it can lead to serious complications such as stroke, amputation and death.

12 Feb 2010

VR technology plays important role in treating patients with PTSD

Posttraumatic stress disorder (PTSD) threatens to overload healthcare and social support systems worldwide as the number of cases rises and existing treatments are not sufficiently effective.

12 Feb 2010

Viral Genetics: Company update

Our mission is to bring new drug compounds to the marketplace. And we've never been in a stronger position to deliver on that promise. We've built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer to clinical trials.

12 Feb 2010

Histone modifications associated with pancreatic cancer development and progression

Specific chemical modifications to proteins called histones, which are found in the nucleus of cells and act as spools around which DNA is wound, can be used to predict prognosis and response to treatment in subsets patients with pancreatic cancer, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found.

12 Feb 2010

New project to unravel secret lives of cancer cells may help produce new cancer therapies

A team of scientists from Princeton University and The Cancer Institute of New Jersey has embarked on a major new project to unravel the secret lives of cancer cells that go dormant and self-cannibalize to survive periods of stress. The work may help produce new cancer therapies to stem changes that render cancer cells dangerous and resistant to treatment.

12 Feb 2010

New pain management options for patients undergoing knee or hip replacements

Patients undergoing knee or hip replacements recover more quickly when treated with targeted pain-blocking medications that may eliminate the need for general anesthesia during surgery and intravenous narcotics drugs after surgery.

12 Feb 2010

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia's latest clinical results follow two earlier successful phase II studies with the company's T-cell vaccine against cat allergy.

12 Feb 2010

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.

12 Feb 2010

MITA endorses eight key principles to reduce unnecessary radiation exposure and medical errors

The Medical Imaging & Technology Alliance (MITA), the leading association representing the manufacturers, innovators and developers of medical imaging and radiation therapy systems, today endorsed eight key principles to reduce exposure to unnecessary medical radiation, further minimize medical errors and improve reporting of adverse events.

12 Feb 2010

Study shows benefits of stent grafts over balloon angioplasty for patients who undergo dialysis

A randomized multicenter study of 190 patients at 13 medical centers shows-- for the first time-- the "superior" benefit of stent grafts over balloon angioplasty for maintaining function of dialysis access grafts in kidney failure patients who undergo dialysis. Until now, no other therapy has proven more effective than angioplasty.

12 Feb 2010

Sun Knowledge to attend Annual Drug Benefit Conference in Phoenix

Sun Knowledge, Ltd., a leading Healthcare Insurance provider of Knowledge Process Outsourcing (KPO) services, will attend the Pharmacy Benefit Management Institute’s Annual Drug Benefit Conference in Phoenix, Az., from February 17-19.

12 Feb 2010

Center for Adolescent Bariatric Surgery performs 100th LAGB procedure

Few treatments are available to help obese adolescents who are unable to lose weight and are already suffering from obesity-related health problems. Laparoscopic adjustable gastric banding (LAGB), an option for adults in the United States since 2001, is showing promise for teens. The Center for Adolescent Bariatric Surgery, which opened at NewYork-Presbyterian Morgan Stanley Children's Hospital in 2006, recently performed its 100th LAGB procedure.

12 Feb 2010

Article features pelvic health problems, risk factors and treatment options for women

Pelvic health concerns in women are common -- yet how the issues impact sexuality and childbearing is not often discussed, according to Mayo Clinic Women's HealthSource.

12 Feb 2010

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

12 Feb 2010

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.

12 Feb 2010

AMC receives GWTG-Stroke Gold Performance Achievement Award for caring stroke patients

Adventist Medical Center recently received the American Heart Association/American Stroke Association's Get With The Guidelines (GWTG) - Stroke Gold Performance Achievement Award. The award recognizes AMC's commitment and success in implementing a higher standard of stroke care by ensuring that stroke patients receive treatment according to nationally accepted standards and recommendations provided by the AHA/ASA.

12 Feb 2010

Therapy News and Research

p62 and ERK proteins lead to development of obesity and insulin resistance, say scientists

Spanish-language media campaign increases number of QuitLine callers

Merck returns worldwide development and commercialization rights for AN2690 to Anacor Pharmaceuticals

New research finds sensory cortex develops late in fragile X syndrome defect

Adult stem cell transplant therapy may help prevent amputations from PAD

VR technology plays important role in treating patients with PTSD

Viral Genetics: Company update

Histone modifications associated with pancreatic cancer development and progression

New project to unravel secret lives of cancer cells may help produce new cancer therapies

New pain management options for patients undergoing knee or hip replacements

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

MITA endorses eight key principles to reduce unnecessary radiation exposure and medical errors

Study shows benefits of stent grafts over balloon angioplasty for patients who undergo dialysis

Sun Knowledge to attend Annual Drug Benefit Conference in Phoenix

Center for Adolescent Bariatric Surgery performs 100th LAGB procedure

Article features pelvic health problems, risk factors and treatment options for women

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

AMC receives GWTG-Stroke Gold Performance Achievement Award for caring stroke patients

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News